First Domestic ROR1 ADC Goes Global; XtalPi Announces HK$2.088 Billion Placing
XtalPi
Computation-Driven Innovative Drug R&D Provider
Genuine Biotech
Innovative Drug Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
China-produced ROR1 ADC Opens the Curtain for Overseas Expansion.
On February 19, Shijiazhuang Pharmaceutical Group announced that its subsidiary, Jushi Biopharmaceuticals, had reached an agreement with Radiance Biopharma. The latter will obtain the development and commercialization rights of Jushi Biopharmaceuticals' self-developed recombinant anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate SYS6005 project within a certain regional scope.
XtalPi Continues to Gain Recognition in the Capital Market.
On February 19, XtalPi announced its plan to raise HKD 2.088 billion through a rights issue, with the price per share set at HKD 6.1.
Star Enterprise of COVID-19 Oral Drugs, Henan Zhenzhen Biotechnology Co., Ltd., Files for IPO Again.
On February 18, according to the Hong Kong Stock Exchange's official website, Henan Zhenzhen Biotechnology Co., Ltd. submitted an application for listing on the Hong Kong Stock Exchange. Zhenzhen Biotechnology is committed to exploring and solving the issue of drug resistance in existing treatment options within the antiviral and anti-tumor fields. Its current core product is Azvudine, an innovative Class 1.1 original new drug.
In the past day, what hotspots in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Antengene Announces Plan to Access DeepSeek to Accelerate Subsequent Pipeline R&D
On February 19, Antengene announced that the company plans to increase investment and integrate resources to establish a dedicated AI department. This initiative includes the local deployment of DeepSeek to accelerate the R&D of subsequent pipelines for the T-cell engager (TCE) platform with steric hindrance shielding effects.
2) ROR1 ADC from Shijiazhuang Pharmaceutical Group Goes Overseas
On February 19, Shijiazhuang Pharmaceutical Group announced that its subsidiary, Jushi Biopharmaceuticals, had reached an agreement with Radiance Biopharma. The latter will obtain the rights for development and commercialization of Jushi Biopharmaceuticals' self-developed recombinant anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate SYS6005 project within a certain regional scope.
3) Pharmaron Completes Controlling Stake in HAIHE MindCure
On February 19, Pharmaron announced that its subsidiary, Pharmaron Clinical, had completed the controlling transaction of Zhejiang Haizhi Mindtech Co., Ltd.
4) Shi Mu Appointed as Head of Takeda China Oncology
Recently, Takeda China's Oncology Division has announced a new personnel appointment. Starting from February 17, 2025, Shi Mu will officially join Takeda China as the head of the Oncology Division, reporting directly to the senior management of Takeda China.
/ 02 /
Capital Information
1) XtalPi Raises HKD 2.088 Billion in Rights Issue
On February 19, XtalPi announced its plan to raise HKD 2.088 billion through a rights issue, with the price per share set at HKD 6.1.
2) Henan Zhenzhen Biotechnology Co., Ltd. applies for listing on the Hong Kong Stock Exchange
On February 18, according to the Hong Kong Stock Exchange website, Henan Zhenzhen Biotechnology Co., Ltd. submitted an application for listing on the Hong Kong Stock Exchange. Zhenzhen Biotechnology is committed to exploring and solving the issue of drug resistance in existing treatment solutions within the antiviral and anti-tumor fields, with its current core product being the innovative Class 1.1 drug Azvudine.
/ 03 /
Pharmaceutical News
1) Anthos Care Bio NKC007 Cell Injection Receives Clinical Approval
On February 19, according to the CDE official website, Enkai Sai Biotechnology's NKC007 cell injection received clinical approval and is intended for use in relapsed/refractory acute myeloid leukemia.
2) Sinovac Zhongwei's Freeze-Dried Respiratory Syncytial Virus mRNA Vaccine Receives Clinical Approval
On February 19, according to the CDE official website, Sinovac Weihan's lyophilized respiratory syncytial virus mRNA vaccine received clinical approval for the prevention of lower respiratory tract diseases caused by respiratory syncytial virus infection.
3) NCR101 Injection from Zhongsheng Suyuan Receives Clinical Approval
On February 19, according to the CDE official website, Zhongsheng Suyuan's NCR101 injection has been granted clinical approval for the proposed study on treating interstitial lung disease.
4) SIR2501 Tablets by Vitarilon Receive Clinical Approval
On February 19, according to the CDE official website, Sirtxin Therapeutics' SIR2501 tablet received clinical approval and is proposed to initiate research for the treatment of amyotrophic lateral sclerosis.
5) Henlius' Fourth Product Approved Overseas
On February 19, Henlius announced that its self-developed and produced Hanbeitai® (Bevacizumab Injection) has officially been approved for marketing by Bolivia's National Drug and Health Technology Agency, under the trade name LONGIVA. This is the fourth product independently developed and produced by Henlius to gain approval for overseas markets.
/ 04 /
Instrument Tracking
1) Kexin Medical Semi-Automatic External Defibrillator Not Registered
On February 19, according to the NMPA website, Corexin Medical's semi-automatic external defibrillator was not registered.
2) Jianjia Medical Technology's Orthopedic Surgical Navigation and Positioning System Receives Registration Approval
On February 19, according to the NMPA website, Jianjia Medical Technology's orthopedic surgical navigation and positioning system obtained registration approval.
/ 05 /
Digital Healthcare Daily
1) iFlytek Medical and Yima Sunshine Reach Strategic Cooperation
On February 19, iFlytek Healthcare Technology announced that it had recently entered into a strategic cooperation agreement with Yimai Sunshine. The two parties plan to collaborate in areas such as business market development, in-depth cooperation on advantageous products and business models, designing innovative investment models for smart healthcare businesses, co-research and development of vertical cognitive large models for healthcare and AI diagnostic large models for medical imaging, and jointly exploring intelligent health management.
2) Fosun Health Cloud HIS Launches DeepSeek AI Assistant
Recently, Fosun Health Cloud HIS (a new-generation intelligent medical cloud platform) has integrated DeepSeek-R1 Full Version to launch a brand-new AI assistant on the cloud HIS platform. This assistant has been simultaneously rolled out in four hospitals under Fosun Health in the Greater Bay Area. The assistant can efficiently analyze patient medical records, provide highly targeted diagnostic suggestions for doctors, and recommend highly personalized treatment plans by deeply integrating massive clinical case data with cutting-edge medical research results based on individual patient differences.
3) Relaxed Health Group Fully Integrates DeepSeek
Recently, Easy Health Group announced the completion of technical integration with DeepSeek.
/ 06 /
Global Pharma News
1) Novo Nordisk applies for freezing Henry Pharmaceutical assets
On February 14, Novo Nordisk filed an application for a freezing order with the Singapore International Commercial Court, requesting to freeze the assets of Henry Pharmaceuticals and Huang Zhenhua in Singapore. Novo claimed that KBP intentionally concealed unfavorable data from the clinical trials of Ocedurenone, a drug for treating hypertension and kidney disease, thereby misleading them into the acquisition. Novo plans to initiate arbitration and claim $830 million in damages.
2) Bayer's Parkinson's Disease Gene Therapy Receives FDA Regenerative Medicine Advanced Therapy Designation
On February 19, AskBio, a gene therapy subsidiary wholly owned and independently operated by Bayer, announced that its gene therapy drug AB-1005 for the treatment of Parkinson's disease has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA.
PS: Welcome to scan the QR code below to add the WeChat ID of AminoJun for communication.
